Difficult to Healing of Skin Ulcers Clinical Trial
— UC-MSCsOfficial title:
Umbilical Cord Mesenchymal Stem Cells Between Gel Treatment Difficult Skin Ulcer Healing Efficacy and Safety of Random, Open, Before-and-after Study
Verified date | February 2016 |
Source | Chinese PLA General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Ethics Committee |
Study type | Interventional |
This study for a six-month trials, Randomized, open, and parallel comparison before and after its own, Stage test includes screening stage, treatment period and follow-up period. In accordance with chronic wound criteria for the patient, By producing the principle of random number, Were randomly divided into UC-MSCs Gel group or Gel group, The researchers according to the situation of wound healing time and decided to use the secondary treatment, To observe the clinical efficacy and safety.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 17 Years to 78 Years |
Eligibility |
Inclusion Criteria: - Older than 17 year old male or female (pregnancy); - Has the ability to care for, has the ability to self signed informed consent, 7 to 17 years of age must be signed by the guardian informed consent; - The process of psychological stability, can finish the tes Exclusion Criteria: - Allergic constitution, or known allergic to pork or beef source products, gao min physique person; - The wound is more than 10 cm by 10 cm; - People with mental illness, drug abusers and or other items; - 1 month used or are using the sugar metabolism of drugs, such as corticosteroids, thiazide diuretics, tricyclic antidepressants, etc; - 3 month participated in other similar test; - Serious infectious disease not controller; - With surgery, such as severe trauma stress situation; - Always had a history of tumor; - Clinical researchers or for other reasons can't cooperate with the doctors, and other information is not suitable for clinical study of patients. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Chinese PLA General Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Chinese PLA General Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of Adverse Events | Frequency and severity of Adverse Events | 6 months | Yes |
Secondary | Relative Wound Area Regression of 40% or More at 6 Week | 6 week | Yes |